Literature DB >> 21320479

Day-to-day variation of late-night salivary cortisol in healthy voluntaries.

Gregori Casals1, Laura Foj, María Jesús Martínez de Osaba.   

Abstract

OBJECTIVES: The study examines the components of biological variation of nocturnal salivary cortisol in healthy subjects. DESIGN AND METHODS: Eight repetitive measurements were performed in seven subjects during a 25-day time period (study A), and then, for comparison, two salivary specimens were taken during two consecutive days from 20 subjects (study B). Salivary cortisol was measured with the Salimetrics HS-Cortisol assay.
RESULTS: Mean salivary cortisol (1.27 nmol/L), analytical variation (CVa=15.4%), within-subject variation (CVi=34.1%), between-subject variation (CVg=35.3%), index of individuality (II=1.06) and reference change value (RCV=104%) were obtained for study A. Similar results were obtained from the set of samples of study B.
CONCLUSION: The study results show a medium degree of individuality for salivary cortisol. Both conventional reference values and comparison of serial results may be equally used for clinical interpretation. A change greater of 104% between two successive measurements should be considered significant.
Copyright © 2011 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

Mesh:

Substances:

Year:  2011        PMID: 21320479     DOI: 10.1016/j.clinbiochem.2011.02.003

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  3 in total

1.  Use of late-night salivary cortisol to monitor response to medical treatment in Cushing's disease.

Authors:  John Newell-Price; Rosario Pivonello; Antoine Tabarin; Maria Fleseriu; Przemysław Witek; Mônica R Gadelha; Stephan Petersenn; Libuse Tauchmanova; Shoba Ravichandran; Pritam Gupta; André Lacroix; Beverly M K Biller
Journal:  Eur J Endocrinol       Date:  2020-02       Impact factor: 6.664

2.  Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushing's disease: 12-month, Phase III pasireotide study.

Authors:  James W Findling; Maria Fleseriu; John Newell-Price; Stephan Petersenn; Rosario Pivonello; Albert Kandra; Alberto M Pedroncelli; Beverly M K Biller
Journal:  Endocrine       Date:  2016-05-21       Impact factor: 3.633

Review 3.  Cortisol Measurements in Cushing's Syndrome: Immunoassay or Mass Spectrometry?

Authors:  Gregori Casals; Felicia Alexandra Hanzu
Journal:  Ann Lab Med       Date:  2020-07       Impact factor: 3.464

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.